| 骨科儿科公司 | | |
![]() |
|
| | | | | | | | | | | | | |
| | |
每股
|
| |
共计
|
| ||||||
公开发行价格 | | | | $ | 27.00 | | | | | $ | 40,500,000 | | |
承保折扣(1) | | | | $ | 1.62 | | | | | $ | 2,430,000 | | |
除支出外,还向矫形儿科公司收取款项。 | | | | $ | 25.38 | | | | | $ | 38,070,000 | | |
| | | | | | | | | | | | | |
| | |
页
|
| |||
招股章程补充 | | | | | | | |
关于本招股说明书的补充
|
| | | | S-ii | | |
关于前瞻性语句的特别说明
|
| | | | S-iii | | |
招股说明书补充摘要
|
| | | | S-1 | | |
RISK FACTORS
|
| | | | S-12 | | |
USE OF PROCEEDS
|
| | | | S-18 | | |
DILUTION
|
| | | | S-19 | | |
DIVIDEND POLICY
|
| | | | S-20 | | |
CAPITALIZATION
|
| | | | S-21 | | |
美国联邦所得税对非美国国有股持有者的影响
|
| | | | S-22 | | |
UNDERWRITING
|
| | | | S-27 | | |
LEGAL MATTERS
|
| | | | S-35 | | |
EXPERTS
|
| | | | S-35 | | |
在其中可以找到更多信息
|
| | | | S-35 | | |
引用注册
|
| | | | S-35 | | |
招股说明书 | | | |||||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
在其中可以找到更多信息
|
| | | | 2 | | |
引用注册
|
| | | | 3 | | |
THE COMPANY
|
| | | | 4 | | |
根据本招股说明书提供的产品
|
| | | | 7 | | |
RISK FACTORS
|
| | | | 8 | | |
关于前瞻性语句的特别说明
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
股本描述
|
| | | | 11 | | |
债务证券的描述
|
| | | | 16 | | |
DESCRIPTION OF WARRANTS
|
| | | | 23 | | |
证券的合法所有权
|
| | | | 25 | | |
SELLING STOCKHOLDERS
|
| | | | 28 | | |
PLAN OF DISTRIBUTION
|
| | | | 29 | | |
LEGAL MATTERS
|
| | | | 31 | | |
EXPERTS
|
| | | | 31 | | |
| | |
截至12月31日的年度,
|
| |
截至9月30日的9个月,
|
| ||||||||||||||||||||||||
(单位:千,份额和人均除外)
分享资料) |
| |
2015
|
| |
2016
|
| |
2017
|
| |
2017
|
| |
2018
|
| |||||||||||||||
业务报表数据: | | | | | | | |||||||||||||||||||||||||
净收入
|
| | | $ | 31,004 | | | | | $ | 37,298 | | | | | $ | 45,620 | | | | | $ | 33,939 | | | | | $ | 42,991 | | |
收入成本
|
| | | | 9,367 | | | | | | 10,931 | | | | | | 11,170 | | | | | | 8,321 | | | | | | 10,825 | | |
毛利
|
| | | | 21,637 | | | | | | 26,367 | | | | | | 34,450 | | | | | | 25,618 | | | | | | 32,166 | | |
业务费用: | | | | | | | |||||||||||||||||||||||||
销售和营销
|
| | | | 15,033 | | | | | | 16,661 | | | | | | 20,527 | | | | | | 15,122 | | | | | | 20,005 | | |
一般和行政
|
| | | | 11,407 | | | | | | 11,631 | | | | | | 16,972 | | | | | | 10,282 | | | | | | 16,393 | | |
首次公开发行成本
|
| | | | — | | | | | | 1,979 | | | | | | — | | | | | | — | | | | | | — | | |
研发
|
| | | | 1,789 | | | | | | 2,223 | | | | | | 3,423 | | | | | | 2,482 | | | | | | 3,455 | | |
业务费用共计
|
| | | | 28,229 | | | | | | 32,494 | | | | | | 40,922 | | | | | | 27,886 | | | | | | 39,853 | | |
营运损失
|
| | | | (6,592) | | | | | | (6,127) | | | | | | (6,472) | | | | | | (2,268) | | | | | | (7,687) | | |
其他费用: | | | | | | | |||||||||||||||||||||||||
利息费用
|
| | | | 1,230 | | | | | | 1,476 | | | | | | 2,490 | | | | | | 1,857 | | | | | | 1,722 | | |
其他费用(收入)
|
| | | | 31 | | | | | | (1,031) | | | | | | (30) | | | | | | (38) | | | | | | 148 | | |
其他费用共计
|
| | | | 1,261 | | | | | | 445 | | | | | | 2,460 | | | | | | 1,819 | | | | | | 1,870 | | |
持续业务净亏损
|
| | | | (7,853) | | | | | | (6,572) | | | | | | (8,932) | | | | | | (4,087) | | | | | | (9,557) | | |
(收益)停业造成的损失
|
| | | | 38 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
净损失
|
| | | $ | (7,891) | | | | | $ | (6,572) | | | | | $ | (8,932) | | | | | $ | (4,087) | | | | | $ | (9,557) | | |
共同造成的净亏损
股东 |
| | | $ | (12,688) | | | | | $ | (12,448) | | | | | $ | (23,530) | | | | | $ | (8,451) | | | | | $ | (9,557) | | |
加权平均股票 - Basic
稀释 |
| | | | 1,744,356 | | | | | | 1,744,356 | | | | | | 4,017,330 | | | | | | 1,754,576 | | | | | | 12,417,972 | | |
每股净亏损
共同股东(1): |
| | | | | | |||||||||||||||||||||||||
碱性稀释
|
| | | $ | (7.27) | | | | | $ | (7.14) | | | | | $ | (5.86) | | | | | $ | (4.82) | | | | | $ | (0.77) | | |
|
| | |
截至2018年9月30日
|
| |||||||||
(单位:千)
|
| |
实际
|
| |
如
调整后(1) |
| ||||||
资产负债表数据: | | | | ||||||||||
现金
|
| | | $ | 24,463 | | | | | $ | 62,183 | | |
周转资金(2)
|
| | | | 50,928 | | | | | | 88,648 | | |
总资产
|
| | | | 76,878 | | | | | | 114,598 | | |
长期负债总额
|
| | | | 25,277 | | | | | | 25,277 | | |
负债总额
|
| | | | 36,193 | | | | | | 36,193 | | |
股东权益总额
|
| | | | 40,685 | | | | | | 78,405 | | |
| | |
三个月结束
九月三十日 |
| |
九个月结束
九月三十日 |
| ||||||||||||||||||
| | |
(未经审计)
(单位:千) |
| |||||||||||||||||||||
| | |
2018
|
| |
2017
|
| |
2018
|
| |
2017
|
| ||||||||||||
净损失
|
| | | $ | (1,865) | | | | | $ | (1,537) | | | | | $ | (9,557) | | | | | $ | (4,087) | | |
利息费用,净额
|
| | | | 608 | | | | | | 761 | | | | | | 1,722 | | | | | | 1,856 | | |
其他费用(收入)
|
| | | | 85 | | | | | | 20 | | | | | | 148 | | | | | | (38) | | |
折旧和摊销
|
| | | | 777 | | | | | | 656 | | | | | | 2,177 | | | | | | 1,748 | | |
股票补偿
|
| | | | 594 | | | | | | 394 | | | | | | 1,239 | | | | | | 1,121 | | |
在我们的首次公开募股时加快限制股票的归属
|
| | | | — | | | | | | — | | | | | | 1,986 | | | | | | — | | |
上市公司成本
|
| | | | 340 | | | | | | — | | | | | | 1,014 | | | | | | — | | |
非经常性专业服务费用
|
| | | | 473 | | | | | | — | | | | | | 2,241 | | | | | | — | | |
调整后的EBITDA
|
| | | $ | 1,012 | | | | | $ | 294 | | | | | $ | 970 | | | | | $ | 600 | | |
|
|
公开发行每股价格
|
| | | | | | | | | $ | 27.00 | | |
|
截至2018年9月30日的历史有形账面价值每股
|
| | | $ | 3.00 | | | | | | | | |
|
可归因于投资者购买本次发行股票的每股有形账面净值增加
|
| | | | 2.32 | | | | | | | | |
|
经调整,截至2018年9月30日每股有形账面价值净额
|
| | | | | | | | | | 5.32 | | |
|
在本次发行中向新投资者稀释每股股份
|
| | | | | | | | | $ | 21.68 | | |
|
| | |
截至2018年9月30日
|
| | |||||||||||
(单位:千,除分享和每股信息外)
|
| |
实际
|
| |
作为调整
|
| | ||||||||
现金
|
| | | $ | 24,463 | | | | | $ | 62,183 | | | | ||
债务总额
|
| | | $ | 25,394 | | | | | $ | 25,394 | | | | ||
股东权益: | | | | | ||||||||||||
普通股,面值0.00025美元;50,000,000股授权;12,807,520股已发行和实际发行;14,307,520股经调整后发行和发行
|
| | | | 2 | | | | | | 4 | | | | ||
额外已付资本
|
| | | | 153,649 | | | | | | 191,367 | | | | ||
累积赤字
|
| | | | (112,623) | | | | | | (112,623) | | | | ||
累计其他综合收入(损失)
|
| | | | (343) | | | | | | (343) | | | | | |
股东权益总额
|
| | | | 40,685 | | | | | | 78,405 | | | | ||
总资本化
|
| | | $ | 66,079 | | | | | $ | 103,799 | | | | ||
|
Underwriters
|
| |
数目
股份 |
| |||
Piper Jaffray&Co.
|
| | | | 630,000 | | |
Stifel,Nicolaus&Company,Instituated
|
| | | | 585,000 | | |
BTIG公司
|
| | | | 142,500 | | |
JMP证券有限责任公司
|
| | | | 142,500 | | |
共计
|
| | | | 1,500,000 | | |
|
| | |
每
分享 |
| |
无
期权 |
| |
带着
期权 |
| |||||||||
公开发行价格
|
| | | $ | 27.00 | | | | | $ | 40,500,000 | | | | | $ | 46,575,000 | | |
承销商折扣
|
| | | $ | 1.62 | | | | | $ | 2,430,000 | | | | | $ | 2,794,500 | | |
支出前的收益给我们
|
| | | $ | 25.38 | | | | | $ | 38,070,000 | | | | | $ | 43,780,500 | | |
|
骨科儿科公司 |
| |
![]() |
|
| | |
页
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
在其中可以找到更多信息
|
| | | | 2 | | |
引用注册
|
| | | | 3 | | |
THE COMPANY
|
| | | | 4 | | |
根据本招股说明书提供的产品
|
| | | | 7 | | |
RISK FACTORS
|
| | | | 8 | | |
关于前瞻性语句的特别说明
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
股本描述
|
| | | | 11 | | |
债务证券的描述
|
| | | | 16 | | |
DESCRIPTION OF WARRANTS
|
| | | | 23 | | |
证券的合法所有权
|
| | | | 25 | | |
SELLING STOCKHOLDERS
|
| | | | 28 | | |
PLAN OF DISTRIBUTION
|
| | | | 29 | | |
LEGAL MATTERS
|
| | | | 31 | | |
EXPERTS
|
| | | | 31 | | |
| 派珀·贾弗雷 | | | | | |
|
|